Skip to main content
Top
Published in: Journal of Neuro-Oncology 1/2009

01-05-2009 | Topic Review

Management of newly diagnosed glioblastoma: guidelines development, value and application

Authors: Jeffrey J. Olson, Camilo E. Fadul, Daniel J. Brat, Srinivasan Mukundan, Timothy C. Ryken

Published in: Journal of Neuro-Oncology | Issue 1/2009

Login to get access

Abstract

The movement to create guidelines for management of medical maladies has been gaining strength for quality, academic, financial and political purposes over the past two decades. This applies to neurological diseases, too. Evidence-based guidelines created in a multidisciplinary fashion using predetermined criteria for grading scientific data and translating this to similarly ranked recommendations is a valuable approach to meeting this goal. The following is a summary of the methods used for, and the results of, an evidence-based guideline for the management of newly diagnosed glioblastoma. In addition to outlining recommendations by discipline, it also addresses how concerns and conflicts were addressed in their development and provides comment on future directions in management of this situation that may improve outcome. It is important that clinicians directly experienced in patient management take the lead in creation of guidelines related to the diseases they deal with, as these clinicians are clearly the most suited to being able to arrive at a meaningful and useful product.
Literature
3.
go back to reference Brem SS, Beirman PJ, Black P, Brem H, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Glass J, Grossman SA, Heimberger AB, Junck L, Linette GP, Loeffler JJ, Maor MH, Moots P, Mrugala M, Nabors LB, Newton HB, Olivi A, Pornow J, Prados M (2008) Central Nervous System cancers, clinical practice guidelines in oncologyTM. J Natl Compr Cancer Cent Netw 6:456–504 Brem SS, Beirman PJ, Black P, Brem H, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Glass J, Grossman SA, Heimberger AB, Junck L, Linette GP, Loeffler JJ, Maor MH, Moots P, Mrugala M, Nabors LB, Newton HB, Olivi A, Pornow J, Prados M (2008) Central Nervous System cancers, clinical practice guidelines in oncologyTM. J Natl Compr Cancer Cent Netw 6:456–504
4.
go back to reference Sackett DL, Straus SE, Richardson WS, Rosenberg W (2000) Evidence-based medicine: how to practice and teach EBM, vol 2. Churchill Livingstone, Edinburgh Sackett DL, Straus SE, Richardson WS, Rosenberg W (2000) Evidence-based medicine: how to practice and teach EBM, vol 2. Churchill Livingstone, Edinburgh
5.
go back to reference Field MJ, Lohr KN (1990) Clinical practice guidelines: directions for a new program. National Academy Press, Washington DC, pp 78–95 Field MJ, Lohr KN (1990) Clinical practice guidelines: directions for a new program. National Academy Press, Washington DC, pp 78–95
9.
go back to reference Walters BC (1998) Clinical practice parameter development in neurosurgery. In: Bean JR (ed) Neurosurgery in transition: the socioeconomic transformation of neurological surgery. Williams and Wilkins, Baltimore, pp 99–111 Walters BC (1998) Clinical practice parameter development in neurosurgery. In: Bean JR (ed) Neurosurgery in transition: the socioeconomic transformation of neurological surgery. Williams and Wilkins, Baltimore, pp 99–111
14.
go back to reference Glioma Meta-analysis Trialists Group (2002) Chemotherapy in adult high-grade gliomas: a systemic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359:1011–1018. doi:10.1016/S0140-6736(02)08091-1 Glioma Meta-analysis Trialists Group (2002) Chemotherapy in adult high-grade gliomas: a systemic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359:1011–1018. doi:10.​1016/​S0140-6736(02)08091-1
16.
go back to reference Methodology of guideline development (2002) Guidelines for the management of acute cervical spine and spinal cord injuries. Neurosurgery 50(3):S2–S6 Methodology of guideline development (2002) Guidelines for the management of acute cervical spine and spinal cord injuries. Neurosurgery 50(3):S2–S6
17.
go back to reference Dean BL, Drayer BP, Bird CR et al (1990) Gliomas: classification with MR imaging. Radiology 174:411–415PubMed Dean BL, Drayer BP, Bird CR et al (1990) Gliomas: classification with MR imaging. Radiology 174:411–415PubMed
18.
go back to reference Amundsen P, Dugstad G, Syvertsen AH (1978) The reliability of computer tomography of the diagnosis and differential diagnosis of meningiomas, gliomas and brain metastases. Acta Neurochir (Wien) 41:177–190. doi:10.1007/BF01809148 Amundsen P, Dugstad G, Syvertsen AH (1978) The reliability of computer tomography of the diagnosis and differential diagnosis of meningiomas, gliomas and brain metastases. Acta Neurochir (Wien) 41:177–190. doi:10.​1007/​BF01809148
19.
go back to reference Carapella CM, Carpinelli G, Knijn A et al (1997) Potential role of in vitro 1H magnetic resonance spectroscopy in the definition of malignancy grading of human neuroepithelial brain tumors. Acta Neurochir Suppl (Wien) 68:127–132 Carapella CM, Carpinelli G, Knijn A et al (1997) Potential role of in vitro 1H magnetic resonance spectroscopy in the definition of malignancy grading of human neuroepithelial brain tumors. Acta Neurochir Suppl (Wien) 68:127–132
20.
go back to reference Reimann B, Papke K, Hoess N et al (2002) Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3- (iodine 123)-L-a-methyltyrosine SPECT. Radiology 225:567–574. doi:10.1148/radiol.2252011431 Reimann B, Papke K, Hoess N et al (2002) Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3- (iodine 123)-L-a-methyltyrosine SPECT. Radiology 225:567–574. doi:10.​1148/​radiol.​2252011431
21.
go back to reference Tamiya T, Kinoshita K, Ono Y et al (2000) Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology 42:333–338. doi:10.1007/s002340050894 PubMed Tamiya T, Kinoshita K, Ono Y et al (2000) Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology 42:333–338. doi:10.​1007/​s002340050894 PubMed
22.
go back to reference Howe FA, Barton SJ, Cudlip SA et al (2003) Metabolic profiles of human brain tumors using quantitative in vivo magnetic resonance 1H spectroscopy. Magn Reson Med 49:223–232. doi:10.1002/mrm.10367 PubMed Howe FA, Barton SJ, Cudlip SA et al (2003) Metabolic profiles of human brain tumors using quantitative in vivo magnetic resonance 1H spectroscopy. Magn Reson Med 49:223–232. doi:10.​1002/​mrm.​10367 PubMed
23.
go back to reference Moller-Hartmann W, Herminghaus S, Krings T et al (2002) Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 44:371–381. doi:10.1007/s00234-001-0760-0 PubMed Moller-Hartmann W, Herminghaus S, Krings T et al (2002) Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 44:371–381. doi:10.​1007/​s00234-001-0760-0 PubMed
24.
go back to reference Lee SJ, Kim JH, Kim YM et al (2001) Perfusion MR imaging in gliomas: comparison with histologic grade. Korean J Radiol 2:1–7PubMed Lee SJ, Kim JH, Kim YM et al (2001) Perfusion MR imaging in gliomas: comparison with histologic grade. Korean J Radiol 2:1–7PubMed
25.
go back to reference Shin JH, Lee HK, Kwun BD et al (2002) Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas. Am J Radiol 179:783–789 Shin JH, Lee HK, Kwun BD et al (2002) Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas. Am J Radiol 179:783–789
26.
go back to reference Roberts HC, Roberts TPL, Bollen AW et al (2001) Correlation of microvascular permeability derived from dynamic contrast enhanced MR imaging with histologic grad and tumor labeling index: a study in human brain tumors. Acad Radiol 8:384–391. doi:10.1016/S1076-6332(03)80545-7 PubMed Roberts HC, Roberts TPL, Bollen AW et al (2001) Correlation of microvascular permeability derived from dynamic contrast enhanced MR imaging with histologic grad and tumor labeling index: a study in human brain tumors. Acad Radiol 8:384–391. doi:10.​1016/​S1076-6332(03)80545-7 PubMed
27.
go back to reference Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95(2):190–198PubMedCrossRef Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95(2):190–198PubMedCrossRef
30.
go back to reference Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J (2003) Debulking or biopsy of malignant glioma in elderly people—a randomised study. Acta Neurochir (Wien) 145(1):5–10. doi:10.1007/s00701-002-1030-6 Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J (2003) Debulking or biopsy of malignant glioma in elderly people—a randomised study. Acta Neurochir (Wien) 145(1):5–10. doi:10.​1007/​s00701-002-1030-6
31.
go back to reference Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomized controlled multicentre phase III trial. Lancet Oncol 7(5):392–401. doi:10.1016/S1470-2045(06)70665-9 PubMed Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomized controlled multicentre phase III trial. Lancet Oncol 7(5):392–401. doi:10.​1016/​S1470-2045(06)70665-9 PubMed
32.
go back to reference Simpson JR, Horton J, Scott C et al (1993) Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26(2):239–244PubMed Simpson JR, Horton J, Scott C et al (1993) Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26(2):239–244PubMed
33.
go back to reference Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M (1987) Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21(2):201–206. doi:10.1097/00006123-198708000-00012 PubMed Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M (1987) Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21(2):201–206. doi:10.​1097/​00006123-198708000-00012 PubMed
34.
go back to reference Levin VA, Wara WM, Davis RL et al (1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 63(2):218–223PubMed Levin VA, Wara WM, Davis RL et al (1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 63(2):218–223PubMed
35.
go back to reference Kiwit JC, Floeth FW, Bock WJ (1996) Survival in malignant glioma: analysis of prognostic factors with special regard to cytoreductive surgery. Zentralbl Neurochir 57(2):76–88PubMed Kiwit JC, Floeth FW, Bock WJ (1996) Survival in malignant glioma: analysis of prognostic factors with special regard to cytoreductive surgery. Zentralbl Neurochir 57(2):76–88PubMed
36.
go back to reference Burger PC, Scheithauer BW, Vogel FS (2002) Surgical pathology of the nervous system and its coverings. Churchill Livingstone, New York Burger PC, Scheithauer BW, Vogel FS (2002) Surgical pathology of the nervous system and its coverings. Churchill Livingstone, New York
37.
go back to reference Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon
38.
go back to reference Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the Central Nervous System. International Agency for Research, Lyon Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the Central Nervous System. International Agency for Research, Lyon
39.
go back to reference Burger PC, Scheithauer BW (1994) Tumors of the Central Nervous System. Armed Forces Institute of Pathology, Washington, DC Burger PC, Scheithauer BW (1994) Tumors of the Central Nervous System. Armed Forces Institute of Pathology, Washington, DC
41.
go back to reference Revesz T, Scaravilli F, Coutinho L et al (1993) Reliability of histological diagnosis including grading in gliomas biopsied by image-guided stereotactic technique. Brain 116(Pt 4):781–793. doi:10.1093/brain/116.4.781 PubMed Revesz T, Scaravilli F, Coutinho L et al (1993) Reliability of histological diagnosis including grading in gliomas biopsied by image-guided stereotactic technique. Brain 116(Pt 4):781–793. doi:10.​1093/​brain/​116.​4.​781 PubMed
42.
go back to reference Gupta M, Djalilvand A, Brat DJ (2005) Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol 124:755–768. doi:10.1309/6JNX4PA60TQ5U5VG PubMed Gupta M, Djalilvand A, Brat DJ (2005) Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol 124:755–768. doi:10.​1309/​6JNX4PA60TQ5U5VG​ PubMed
43.
go back to reference Burger PC, Nelson JS (1997) Stereotactic brain biopsies: specimen preparation and evaluation. Arch Pathol Lab Med 121:477–480PubMed Burger PC, Nelson JS (1997) Stereotactic brain biopsies: specimen preparation and evaluation. Arch Pathol Lab Med 121:477–480PubMed
44.
go back to reference Martinez AJ, Pollack I, Hall WA et al (1988) Touch preparations in the rapid intraoperative diagnosis of Central Nervous System lesions, A comparison with frozen sections and paraffin embedded sections. Mod Pathol 1:378–384PubMed Martinez AJ, Pollack I, Hall WA et al (1988) Touch preparations in the rapid intraoperative diagnosis of Central Nervous System lesions, A comparison with frozen sections and paraffin embedded sections. Mod Pathol 1:378–384PubMed
46.
go back to reference Brainard JA, Prayson RA, Barnett GH (1997) Frozen section evaluation of stereotactic brain biopsies: diagnostic yield at the stereotactic target position in 188 cases. Arch Pathol Lab Med 121:481–484PubMed Brainard JA, Prayson RA, Barnett GH (1997) Frozen section evaluation of stereotactic brain biopsies: diagnostic yield at the stereotactic target position in 188 cases. Arch Pathol Lab Med 121:481–484PubMed
48.
go back to reference Prayson RA, Agamanolis DP, Cohen ML et al (2000) Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading. J Neurol Sci 175:33–39. doi:10.1016/S0022-510X(00)00274-4 PubMed Prayson RA, Agamanolis DP, Cohen ML et al (2000) Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading. J Neurol Sci 175:33–39. doi:10.​1016/​S0022-510X(00)00274-4 PubMed
49.
go back to reference Prayson RA (2002) Cell proliferation and tumors of the Central Nervous System, part II: radiolabeling, cytometric, and immunohistochemical techniques. J Neuropathol Exp Neurol 61:663–672PubMed Prayson RA (2002) Cell proliferation and tumors of the Central Nervous System, part II: radiolabeling, cytometric, and immunohistochemical techniques. J Neuropathol Exp Neurol 61:663–672PubMed
50.
go back to reference McKeever PE, Ross DA, Strawderman MS, Brunberg JA, Greenberg HS, Junck L (1997) A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 56:798–805. doi:10.1097/00005072-199756070-00006 PubMed McKeever PE, Ross DA, Strawderman MS, Brunberg JA, Greenberg HS, Junck L (1997) A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 56:798–805. doi:10.​1097/​00005072-199756070-00006 PubMed
54.
go back to reference Hunter SB, Brat DJ, Olson JJ, Von Deimling A, Zhou W, Van Meir EG (2003) Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy. Int J Oncol 23:857–869 ReviewPubMed Hunter SB, Brat DJ, Olson JJ, Von Deimling A, Zhou W, Van Meir EG (2003) Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy. Int J Oncol 23:857–869 ReviewPubMed
55.
go back to reference Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489PubMed Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489PubMed
56.
57.
go back to reference Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMed Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMed
58.
go back to reference Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW (2003) Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 8:a1–a9. doi:10.2741/896 PubMed Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW (2003) Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 8:a1–a9. doi:10.​2741/​896 PubMed
59.
go back to reference Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479. doi:10.1093/jnci/90.19.1473 PubMed Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479. doi:10.​1093/​jnci/​90.​19.​1473 PubMed
60.
go back to reference Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G et al (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4152. doi:10.1038/sj.onc.1202759 PubMed Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G et al (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4152. doi:10.​1038/​sj.​onc.​1202759 PubMed
61.
go back to reference Aldape K, Burger PC, Perry A (2007) Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131:242–251PubMed Aldape K, Burger PC, Perry A (2007) Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131:242–251PubMed
62.
go back to reference Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190PubMed Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190PubMed
63.
go back to reference McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M et al (2005) The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104:1468–1477. doi:10.1002/cncr.21338 PubMed McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M et al (2005) The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104:1468–1477. doi:10.​1002/​cncr.​21338 PubMed
64.
go back to reference Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, Huntley BK et al (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma, A study of paraffin-embedded sections. Mod Pathol 14:842–853. doi:10.1038/modpathol.3880400 PubMed Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, Huntley BK et al (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma, A study of paraffin-embedded sections. Mod Pathol 14:842–853. doi:10.​1038/​modpathol.​3880400 PubMed
65.
go back to reference Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N et al (2002) Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8:196–201PubMed Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N et al (2002) Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8:196–201PubMed
66.
go back to reference Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB et al (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158:1253–1262PubMed Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB et al (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158:1253–1262PubMed
67.
go back to reference Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G (2003) Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61:267–273. doi:10.1023/A:1022580610598 PubMed Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G (2003) Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61:267–273. doi:10.​1023/​A:​1022580610598 PubMed
68.
go back to reference Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714. doi:10.1200/JCO.2005.04.3414 PubMed Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714. doi:10.​1200/​JCO.​2005.​04.​3414 PubMed
69.
go back to reference Brat DJ, Seiferheld WF, Perry A, Hammond EH, Murray KJ, Schulsinger AR et al (2004) Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Neuro-oncol 6:96–103. doi:10.1215/S1152851703000231 PubMed Brat DJ, Seiferheld WF, Perry A, Hammond EH, Murray KJ, Schulsinger AR et al (2004) Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Neuro-oncol 6:96–103. doi:10.​1215/​S115285170300023​1 PubMed
70.
go back to reference Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B et al (2002) Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61:321–328PubMed Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B et al (2002) Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61:321–328PubMed
71.
go back to reference Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256. doi:10.1093/jnci/93.16.1246 PubMed Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256. doi:10.​1093/​jnci/​93.​16.​1246 PubMed
72.
go back to reference Liu L, Backlund LM, Nilsson BR, Grander D, Ichimura K, Goike HM et al (2005) Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83:917–926. doi:10.1007/s00109-005-0700-2 PubMed Liu L, Backlund LM, Nilsson BR, Grander D, Ichimura K, Goike HM et al (2005) Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83:917–926. doi:10.​1007/​s00109-005-0700-2 PubMed
73.
go back to reference Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387PubMed Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387PubMed
74.
go back to reference Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS et al (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89:2965–2969. doi:10.1073/pnas.89.7.2965 PubMed Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS et al (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89:2965–2969. doi:10.​1073/​pnas.​89.​7.​2965 PubMed
75.
go back to reference Olson JJ, Barnett D, Yang J, Assietti R, Cotsonis G, James CD (1998) Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res 4:215–222PubMed Olson JJ, Barnett D, Yang J, Assietti R, Cotsonis G, James CD (1998) Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res 4:215–222PubMed
76.
go back to reference Huncharek M, Kupelnick B (2000) Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 12:107–112PubMed Huncharek M, Kupelnick B (2000) Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 12:107–112PubMed
77.
go back to reference Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS et al (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61:1122–1128PubMed Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS et al (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61:1122–1128PubMed
78.
go back to reference Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC et al (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700–707PubMed Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC et al (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700–707PubMed
79.
go back to reference Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M et al (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11:1462–1466. doi:10.1158/1078-0432.CCR-04-1737 PubMed Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M et al (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11:1462–1466. doi:10.​1158/​1078-0432.​CCR-04-1737 PubMed
80.
go back to reference Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354. doi:10.1056/NEJM200011093431901 PubMed Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354. doi:10.​1056/​NEJM200011093431​901 PubMed
81.
go back to reference Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330 PubMed Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.​1056/​NEJMoa043330 PubMed
82.
go back to reference Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi:10.1056/NEJMoa043331 PubMed Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi:10.​1056/​NEJMoa043331 PubMed
83.
go back to reference Mikeska T, Bock C, El-Maarri O, Hubner A, Ehrentraut D, Schramm J et al (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9:368–381. doi:10.2353/jmoldx.2007.060167 PubMed Mikeska T, Bock C, El-Maarri O, Hubner A, Ehrentraut D, Schramm J et al (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9:368–381. doi:10.​2353/​jmoldx.​2007.​060167 PubMed
84.
go back to reference Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ et al (2006) O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort. J Clin Oncol 24:3431–3437. doi:10.1200/JCO.2006.05.7265 PubMed Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ et al (2006) O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort. J Clin Oncol 24:3431–3437. doi:10.​1200/​JCO.​2006.​05.​7265 PubMed
85.
go back to reference Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W et al (2006) In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 12:4523–4532. doi:10.1158/1078-0432.CCR-05-1830 PubMed Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W et al (2006) In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 12:4523–4532. doi:10.​1158/​1078-0432.​CCR-05-1830 PubMed
86.
go back to reference Walker MD et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333–343PubMed Walker MD et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333–343PubMed
87.
go back to reference Walker MD et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329PubMed Walker MD et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329PubMed
89.
go back to reference Bleehen NM, Stenning SP (1991) A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma, The Medical Research Council Brain Tumour Working Party. Br J Cancer 64:769–774PubMed Bleehen NM, Stenning SP (1991) A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma, The Medical Research Council Brain Tumour Working Party. Br J Cancer 64:769–774PubMed
90.
go back to reference Nelson DF et al (1993) Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma––possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys 25:193–207PubMed Nelson DF et al (1993) Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma––possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys 25:193–207PubMed
91.
92.
go back to reference Phillips C et al (2003) A randomized trial comparing 35 Gy in ten fractions with 60 Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. Radiother Oncol 68:23–26. doi:10.1016/S0167-8140(03)00206-8 PubMed Phillips C et al (2003) A randomized trial comparing 35 Gy in ten fractions with 60 Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. Radiother Oncol 68:23–26. doi:10.​1016/​S0167-8140(03)00206-8 PubMed
93.
94.
go back to reference Glinski B (1993) Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas, A preliminary report on a randomized trial. J Neurooncol 16:167–172. doi:10.1007/BF01324704 PubMed Glinski B (1993) Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas, A preliminary report on a randomized trial. J Neurooncol 16:167–172. doi:10.​1007/​BF01324704 PubMed
95.
go back to reference Prados MD et al (2001) Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 49:71–77. doi:10.1016/S0360-3016(00)01458-9 PubMed Prados MD et al (2001) Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 49:71–77. doi:10.​1016/​S0360-3016(00)01458-9 PubMed
96.
go back to reference Deutsch M et al (1989) Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 16:1389–1396PubMed Deutsch M et al (1989) Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 16:1389–1396PubMed
97.
go back to reference Ludgate CM et al (1988) Superfractionated radiotherapy in grade III, IV intracranial gliomas. Int J Radiat Oncol Biol Phys 15:1091–1095PubMed Ludgate CM et al (1988) Superfractionated radiotherapy in grade III, IV intracranial gliomas. Int J Radiat Oncol Biol Phys 15:1091–1095PubMed
99.
go back to reference Fulton DS et al (1984) Misonidazole combined with hyperfractionation in the management of malignant glioma. Int J Radiat Oncol Biol Phys 10:1709–1712PubMed Fulton DS et al (1984) Misonidazole combined with hyperfractionation in the management of malignant glioma. Int J Radiat Oncol Biol Phys 10:1709–1712PubMed
103.
go back to reference Selker RG et al (2002) The Brain Tumor Cooperative Group NIH Trial 87–01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51:343–355. doi:10.1097/00006123-200208000-00009 (discussion 355–357)PubMed Selker RG et al (2002) The Brain Tumor Cooperative Group NIH Trial 87–01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51:343–355. doi:10.​1097/​00006123-200208000-00009 (discussion 355–357)PubMed
104.
go back to reference Souhami L et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93–05 protocol. Int J Radiat Oncol Biol Phys 60:853–860. doi:10.1016/j.ijrobp.2004.04.011 PubMed Souhami L et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93–05 protocol. Int J Radiat Oncol Biol Phys 60:853–860. doi:10.​1016/​j.​ijrobp.​2004.​04.​011 PubMed
105.
106.
go back to reference Massey V, Wallner K (1990) Patterns of second recurrence of malignant astrocytomas. Int J Radiat Oncol Biol Phys 18:395–398PubMed Massey V, Wallner K (1990) Patterns of second recurrence of malignant astrocytomas. Int J Radiat Oncol Biol Phys 18:395–398PubMed
107.
go back to reference Wallner K et al (1989) Patterns of failure following treatment for glioblastoma and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409PubMed Wallner K et al (1989) Patterns of failure following treatment for glioblastoma and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409PubMed
108.
go back to reference Shapiro WR et al (1989) Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71:1–9PubMed Shapiro WR et al (1989) Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71:1–9PubMed
109.
go back to reference Kita M et al (1989) Radiotherapy of malignant glioma––prospective randomized clinical study of whole brain vs local irradiation. Gan no rinsho Jpn J Cancer Clin 35:1289–1294 Kita M et al (1989) Radiotherapy of malignant glioma––prospective randomized clinical study of whole brain vs local irradiation. Gan no rinsho Jpn J Cancer Clin 35:1289–1294
110.
go back to reference Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T (1997) Interstitial chemotherapy with carmustine-loaded polymers for high grade gliomas: a randomized double-blind study. Neurosurgery 41:44–49. doi:10.1097/00006123-199707000-00011 PubMed Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T (1997) Interstitial chemotherapy with carmustine-loaded polymers for high grade gliomas: a randomized double-blind study. Neurosurgery 41:44–49. doi:10.​1097/​00006123-199707000-00011 PubMed
111.
go back to reference Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmistine (BCNU) wafers (Gliadel wafers) in patients with primary malignant gliomas. Neuro-oncol 5:79–88. doi:10.1215/15228517-5-2-79 PubMed Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmistine (BCNU) wafers (Gliadel wafers) in patients with primary malignant gliomas. Neuro-oncol 5:79–88. doi:10.​1215/​15228517-5-2-79 PubMed
112.
113.
go back to reference Chinot OL, Barrie M, Frauger E, Dufour H, Figarella-Branger D, Palmari J et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208–2214. doi:10.1002/cncr.20224 PubMed Chinot OL, Barrie M, Frauger E, Dufour H, Figarella-Branger D, Palmari J et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208–2214. doi:10.​1002/​cncr.​20224 PubMed
114.
go back to reference Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266. doi:10.1002/cncr.11323 PubMed Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266. doi:10.​1002/​cncr.​11323 PubMed
116.
118.
go back to reference Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760. doi:10.1038/nature05236 PubMed Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760. doi:10.​1038/​nature05236 PubMed
119.
go back to reference Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. doi:10.1038/nature03128 PubMed Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. doi:10.​1038/​nature03128 PubMed
120.
go back to reference Khwaja FW, Duke-Cohan JS, Brat DJ, Van Meir EG (2006) Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration. Clin Cancer Res 12:6331–6336. doi:10.1158/1078-0432.CCR-06-1296 PubMed Khwaja FW, Duke-Cohan JS, Brat DJ, Van Meir EG (2006) Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration. Clin Cancer Res 12:6331–6336. doi:10.​1158/​1078-0432.​CCR-06-1296 PubMed
121.
go back to reference Khwaja FW, Nolen JD, Mendrinos SE, Lewis MM, Olson JJ, Pohl J et al (2006) Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the Central Nervous System and identifies specific protein markers. Proteomics 6:6277–6287. doi:10.1002/pmic.200600135 PubMed Khwaja FW, Nolen JD, Mendrinos SE, Lewis MM, Olson JJ, Pohl J et al (2006) Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the Central Nervous System and identifies specific protein markers. Proteomics 6:6277–6287. doi:10.​1002/​pmic.​200600135 PubMed
122.
go back to reference Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173. doi:10.1016/j.ccr.2006.02.019 PubMed Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173. doi:10.​1016/​j.​ccr.​2006.​02.​019 PubMed
123.
go back to reference Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C et al (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602–1607PubMed Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C et al (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602–1607PubMed
124.
go back to reference Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME et al (2002) Prediction of Central Nervous System embryonal tumour outcome based on gene expression. Nature 415:436–442. doi:10.1038/415436a PubMed Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME et al (2002) Prediction of Central Nervous System embryonal tumour outcome based on gene expression. Nature 415:436–442. doi:10.​1038/​415436a PubMed
125.
go back to reference Buatti J, Ryken R, Smith MC, Sneed P, Suh J, Mehta M, Olson JJ (2008) Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. J Neurooncol 89:313–337. doi:10.1007/s11060-008-9617-2 PubMed Buatti J, Ryken R, Smith MC, Sneed P, Suh J, Mehta M, Olson JJ (2008) Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. J Neurooncol 89:313–337. doi:10.​1007/​s11060-008-9617-2 PubMed
127.
go back to reference Quinn JA, Desjardins A, Weingart J et al (2005) Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23:7178–7187. doi:10.1200/JCO.2005.06.502 PubMed Quinn JA, Desjardins A, Weingart J et al (2005) Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23:7178–7187. doi:10.​1200/​JCO.​2005.​06.​502 PubMed
128.
go back to reference Barvaux VA, Ranson M, Brown R et al (2004) Dual repair modulation reverses Temozolomide resistance in vitro. Mol Cancer Ther 3:123–127PubMed Barvaux VA, Ranson M, Brown R et al (2004) Dual repair modulation reverses Temozolomide resistance in vitro. Mol Cancer Ther 3:123–127PubMed
129.
go back to reference Woolford LB, Southgate TD, Margison GP et al (2006) The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine. J Gene Med 8:29–34. doi:10.1002/jgm.816 PubMed Woolford LB, Southgate TD, Margison GP et al (2006) The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine. J Gene Med 8:29–34. doi:10.​1002/​jgm.​816 PubMed
130.
go back to reference Plummer R, Middleton M, Wilson R, et al. (2005) Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Abstr B268 Plummer R, Middleton M, Wilson R, et al. (2005) Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Abstr B268
132.
go back to reference Tentori L, Leonetti C, Scarsella M et al (2005) Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int J Oncol 26:415–422PubMed Tentori L, Leonetti C, Scarsella M et al (2005) Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int J Oncol 26:415–422PubMed
133.
go back to reference Weaver KD, Yeyeodu S, Cusack JC Jr, Baldwin AS Jr, Ewend MG (2003) Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61:187–196. doi:10.1023/A:1022554824129 PubMed Weaver KD, Yeyeodu S, Cusack JC Jr, Baldwin AS Jr, Ewend MG (2003) Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61:187–196. doi:10.​1023/​A:​1022554824129 PubMed
134.
137.
go back to reference Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC (2004) PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 55:426–432PubMed Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC (2004) PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 55:426–432PubMed
138.
go back to reference Herbst RS, Heymach JV, O’Reilly MS, Onn A, Ryan AJ (2007) Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16:239–249. doi:10.1517/13543784.16.2.239 PubMed Herbst RS, Heymach JV, O’Reilly MS, Onn A, Ryan AJ (2007) Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16:239–249. doi:10.​1517/​13543784.​16.​2.​239 PubMed
139.
go back to reference Brockman J (1996) The third culture: beyond scientific revolution. Simon and Schuster, New York Brockman J (1996) The third culture: beyond scientific revolution. Simon and Schuster, New York
Metadata
Title
Management of newly diagnosed glioblastoma: guidelines development, value and application
Authors
Jeffrey J. Olson
Camilo E. Fadul
Daniel J. Brat
Srinivasan Mukundan
Timothy C. Ryken
Publication date
01-05-2009
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 1/2009
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-009-9838-z

Other articles of this Issue 1/2009

Journal of Neuro-Oncology 1/2009 Go to the issue